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Previously, the interest in in vivo/in vitro correlations
in the dermal ®eld of research has increased steadily.
Unfortunately, in most cases the skin from different
human donors was taken for in vivo and in vitro
experiments, which led to problems concerning the
interindividual variability of the skin. Therefore, we
established a methodology to utilize the same skin
for both sets of data. In time dependency, drug
amounts in the stratum corneum and the deeper skin
layers were determined from eight donors using the
same skin area for in vivo and the corresponding
in vitro tests. Penetration experiments were carried
out with the lipophilic drug ¯ufenamic acid dissolved
in wool alcohols ointment as the model formulation,
which was administered to the skin under ``in®nite
dose'' conditions. At different time points prior to
starting the surgery, the drug preparation was
applied topically on the edges of the skin area, which
was planned for excision using Finn chambers. After
anesthetizing the patient and disinfecting the oper-
ation area, the incubated skin pieces were cut off
®rst and immediately frozen to limit further drug
diffusion. In vitro experiments were performed on
the remaining skin ¯ap, using two different test sys-
tems, a penetration and a permeation model. At the
end of all experiments (in vivo and in vitro) the skin
specimens were segmented horizontally and the drug
was extracted and quanti®ed. The in vivo and in vitro
drug amounts in the stratum corneum and the
deeper skin layers, respectively, were compared. The
inevitable use of unknown volumes of disinfectant
in vivo (medical reasons) might be the reason why a
correlation failed for the stratum corneum.
Nevertheless, for both in vitro test systems a direct
linear correlation was found for the deeper skin
layers, which showed slopes of a = 3.2272 6 0.3933
(penetration model vs in vivo) and a = 1.7776 6
0. 1926 (permeation model vs in vivo). This difference
demonstrates the varying in¯uence of the test sys-
tems and represents a factor about which in vivo and
in vitro data are shifted against each other. As far as
the model drug ¯ufenamic acid is concerned, this
methodology represents a tool to predict drug
penetration into the deeper skin layers in vivo after
carrying out corresponding in vitro experiments.
Therefore, the potential is given to reduce the num-
ber of in vivo experiments, the risk for the volunteers,
and the costs for the development of new drug
preparations. Key words: deeper skin layers/drug penetra-
tion/¯ufenamic acid/Franz diffusion cell/human skin/
in vitro/in vivo/Saarbruecken penetration model. J Invest
Dermatol 118:540±544, 2002
P
reviously, many scientists have been interested in
correlating human in vivo and in vitro data in the ®eld
of dermatology and (trans)dermal drug delivery, espe-
cially to test the possibility of decreasing the number of
in vivo studies during formulation development. Only a
limited number of in vivo test methods are suitable for application
on humans, however, e.g., the tape stripping technique, used in
addressing dermatopharmacokinetic questions (Albery and
Hadgraft, 1979; Rougier et al, 1983; Pershing et al, 1992) or the
determination of blood and urine levels, utilized to assess systemic
bioavailability for transdermal delivery (Rougier et al, 1983; Guy
et al, 1986). Zesch and Schaefer (1975) carried out in vivo studies
and explored the amount of penetrated drug in different skin layers.
Unfortunately, corresponding in vitro data of the same skin were
not available. In a previous study (Wagner et al, 2000) we reported
on an in vivo/in vitro correlation for drug penetration data in the
stratum corneum (SC). In the present study we aimed to
demonstrate in the deeper skin layers (DSL) that in vivo data may
also be predicted from in vitro experiments.
To overcome the problem of interindividual and site variability
of lipid composition, pH, and water content within the SC, which
are known to in¯uence signi®cantly the penetration and distribu-
tion of drugs, we introduced an experimental design that allowed
the realization of in vitro and in vivo experiments (SC and DSL) by
using the skin of the same donor. With such sets of data an in vivo/
in vitro correlation for human DSL should be tested. This
information appears to be pivotal for the interpretation of in vitro
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results and may eventually lead to a reduction of the number of
in vivo human studies necessary for the development of dermo-
pharmaceutical drug products.
MATERIALS AND METHODS
Materials The following chemicals and equipment were used:
¯ufenamic acid in the crystalline modi®cation I (Kali-Chemie Pharma,
Hannover, Germany); wool alcohols ointment and Multi®lm kristall-klar
(Beiersdorf, Hamburg, Germany); Ringer solution, Sùrensen phosphate
buffer pH 7.4, McIlvaine citric acid-phosphate buffer pH 2.2 and NaOH
(all components from Merck, Darmstadt, Germany); Plastibase (Heyden
GmbH, MuÈnchen, Germany); Braunoderm (Braun Melsungen AG,
Melsungen, Germany); methanol (Baker, Deventer, the Netherlands);
Finn chambers (Hermal, Reinbek, Germany); Franz diffusion cell type
4G-01-00-20 (Perme Gear, Riegelsville, PA); cryomicrotome HR Mark
II, model 1978 (SLEE, Mainz, Germany); isocratic high-performance
liquid chromatography consisting of a 655 A 40 autosampler, L 4250
detector, L 6220 pump, 6000 K data interface and 5 mm LiChrospher
100/RP-18 column/12.5 cm 3 4 mm (Merck-Hitachi, Darmstadt,
Germany).
Flufenamic acid (0.9% wt/wt) dissolved in wool alcohols ointment
(WAO, German Pharmacopoeia 1999) was taken as the drug preparation
under ``in®nite dose'' conditions (Franz et al, 1993) applying 300 mg per
cm2 (in vitro) and 34 mg per cm2 (in vivo). In contrast to the normal use
of semisolid dosage forms, in®nite dosing was chosen due to the
following reasons: (i) to minimize the in¯uence of the dose (standardized
kinetic conditions); (ii) to achieve higher drug amounts within the skin
(no problems with the detection limit); and (iii) to have a simple
application procedure (recommendation of the ethics committee to
reduce the stress of the patients)
In the crystalline modi®cation I, ¯ufenamic acid has a melting point of
132.8°C and a pKa of 3.9 (Alignente and de Caprariis, 1982). Its
solubility in water is limited, but can be increased with lipophilic solvents
as well as with alkaline solutions. This improvement of the solubility was
made use of by extracting the drug out of the skin samples with NaOH.
At 32°C, 0.9% ¯ufenamic acid is completely dissolved in the ointment
base (Wild, 1988), which was veri®ed by light microscopic inspection.
The ointment base consisted of lipophilic components only; therefore,
¯ufenamic acid was undissociated within the preparation.
Methods
In vivo and in vitro experiments The in vivo study was approved from the
ethics committee of the ``Aerztekammer des Saarlandes'' and the Caritas-
Traegergesellschaft Trier e.V. Eight subjects undergoing abdominal
plastic surgery participated in the study. They were in good health and
had no medical history of any dermatologic disease.
For in vivo experiments, two Finn chambers (15 mm in diameter and
1 mm in depth) ®lled with the drug preparation (about 60 mg) were
applied at marked edges of the skin area, which was planned for excision
(Fig 1) at two different time points before the beginning of the surgery.
As far as possible, incubation times between 30 and 60 min (chamber 1)
as well as 60 and 180 min (chamber 2) were maintained. At the start of
the surgery, directly after anesthetizing the patient, the Finn chambers
were removed and the remaining ointment was wiped off with a piece
of cotton in the direction of the edges of the skin ¯ap to prevent any
contamination of the middle area of the skin. The whole operation area
was disinfected using Braunoderm, an isopropanolic solution of poly-
vinylpyrrolidone-iod. The incubated skin biopsies were cut off, their
subcutaneous fatty tissue was removed and the skin pieces were frozen at
±80°C to limit drug diffusion inside the skin. Afterwards, the rest of the
skin ¯ap was excised, the subcutaneous fatty tissue was also removed and
pieces 10 cm 3 10 cm in size were wrapped in aluminum foil, collected
in an impermeable polyethylene bag and stored for a maximum of 3 mo
in a freezer at ±26°C until use.
For in vitro experiments, skin disks were punched out, thawed, cleaned
with cotton and transferred into the respective test system: the
Saarbruecken penetration model (SB-M) or the Franz diffusion cell (FD-
C).
The SB-M (Fig 2a) is a model to study the rate and the extent of
drugs that penetrated into the SC and the DSL. The drug preparation
was ®lled in a 2 mm deep cavity of a Te¯on punch and applied on the
surface of the skin, which lay in a Te¯on bloc on a ®lter paper soaked
with Ringer solution to prevent water loss from the skin during the
Figure 1. Scheme of the excised skin ¯ap and the arrangement of
the in vivo and in vitro experiments.
Figure 2. In vitro test systems utilized in this study. (a) SB-M, (b)
FD-C.
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experimental time. The Te¯on punch was charged with 500 g for 2 min
to improve the contact between the drug preparation and the skin.
Afterwards, the Te¯on punch was ®xed in its position and the gap
between the two Te¯on parts was sealed with Plastibase. The whole
arrangement was transferred into a plastic box and placed in a water bath
of 32°C for the respective time interval. The ®lter paper beneath the
skin was always tested for its content of ¯ufenamic acid. Using this
model, the skin for itself is the only acceptor for the penetrating drug.
The FD-C (Fig 2b) is a model that was originally developed to study
drug permeation through the skin. In this case, the skin was sandwiched
between two compartments: the donor compartment holds the drug
preparation. To minimize side diffusion of the drug the drug formulation
was applied in the present test series using a plastic cylinder. In addition
to the skin, a Sùrenson phosphate buffer solution pH 7.4, mixed with a
magnetic stirring bar set at 500 r.p.m., served as a supplemental acceptor
compartment. To improve the reproducibility of the experiments, the
skin was always prehydrated with the basolateral acceptor medium for
30 min before the application of the drug formulation. The temperature
of the whole apparatus was regulated using a water jacket ¯owed by
circulating water of 32°C. One sample of the acceptor medium was
always taken before and at the end of the incubation time to have a
blind value of the acceptor medium and to check whether ¯ufenamic
acid had permeated through the skin during the investigated time
intervals.
The in vitro experiments lasted as long as the corresponding in vivo
ones from the same skin ¯ap. According to the in vivo design, the skin
was also treated with Braunoderm directly after the removal of the
ointment using the liquid of four times spraying in each case. Owing to
the limited availability of the skin specimens in some cases, only two
in vitro experiments could be carried out for both test systems and all
investigated incubation times.
Segmentation of the skin All incubated skin biopsies were investigated in
the same way, no matter whether the experiment was done in vivo or
in vitro.
First, the skin was transferred into a so-called stripping apparatus
(Borchert, 1994) where it was mounted on cork disks using small pins.
After covering the skin with a Te¯on mask that released only an area of
15 mm in diameter, the skin was subsequently stripped with 20 pieces of
adhesive tape (size = 15 3 19 mm), applying a weight of 2 kg for 10 s
on the surface of the strip in each case and removing the strip rapidly
afterwards. This methodology resulted in SC layers of nearly the same
thickness (Borchert, 1994; Pershing et al, 1994; Theobald, 1998)
throughout the whole procedure. The ®rst tape strip was always
discarded because of potential contamination by the residual drug on the
surface of the skin (Howes et al, 1996). The rest of the tape strips was
combined in ®ve pools according to the following scheme: one, three,
four, ®ve, and six strips.
Second, the skin was rapidly frozen in a stream of expanding carbon
dioxide, and a specimen with a diameter of 13 mm was taken out of the
stripped area and transferred into a cryomicrotome. The skin was cut
into surface parallel sections (Zesch and Schaefer, 1974) of 25 mm
thickness and collected in 12 centrifuge tubes according to the following
scheme: incomplete cuts, 4 3 2 3 25 mm, 4 3 4 3 25 mm, 2 3 8 3
25 mm, and residual skin rest.
Drug concentration±skin depth pro®les Using a cross-section of the skin of
each subject, the SC thickness' was determined by a light microscopic
procedure. The number of tape strips was linearly correlated with the
thickness of the SC. The thickness of the incomplete cuts and the skin
rests was calculated over their weights relating to a standard cut with
known weight and thickness.
Assay method and high-performance liquid chromatography procedure The
¯ufenamic acid was extracted from the adhesive tape, the skin cuts and
the ®lter paper with 1.5 ml 0.05 M NaOH by shaking for 2 h at room
temperature and centrifugation. For details concerning the high-
performance liquid chromatography procedure see Wagner et al (2000).
RESULTS
Table I illustrates the ¯ufenamic acid amounts that penetrated into
the SC (Table Ia) and the DSL (Table Ib) under in vivo and in vitro
conditions. Each pair of data represents varying experimental times
caused by the routine in the hospital as well as emergency
operations or unexpected problems with the operation before the
``in vivo'' experiment. The planned incubation intervals could not
be maintained in all cases.
In contrast to in vivo data obtained earlier in our laboratory using
the tape stripping technique without any further disinfection of the
incubated skin area (Wagner et al, 2000), in ®ve of eight subjects
the in vivo drug amounts present in the SC after the longer
incubation time were lower than the ones after the shorter
incubation time. Using the in vitro test systems, such circumstances
were only found once for the SB-M and the FD-C, respectively. In
the other in vitro investigations, the drug amounts became higher
with increasing incubation times, or were more or less equal to
each other (considering the relatively high span width), indicating
that steady-state conditions might be reached within the SC. To
examine whether the use of the disinfectant was responsible for the
obtained data, in vitro experiments with and without disinfectant
were carried out. The results are shown in Fig 3 demonstrating
two very different drug concentration±SC depth pro®les that did
not leave any doubt about the in¯uence of the Braunoderm
solution.
In the DSL (Table Ib) statistically signi®cant differences could
be noticed at six data points between the two in vitro models
(Student's t test; p < 0.05). In all subjects, the ¯ufenamic acid
amounts detected in the FD-C were lower than those observed
using the SB-M. Concerning the drug amounts in the DSL in vivo,
the values for all time points were also lower than those observed
with the SB-M. In contrast to these results the drug amounts
achieved with the FD-C after the shorter time intervals were in ®ve
of eight cases even lower than the ones achieved under in vivo
conditions.
Table I. Values of the drug amounts penetrated into the
SC and the DSL in vivo (n = 1) as well as in vitro (n = 2) (ng
per cm2) in dependence on the incubation time (min) and
the test system
Subject
Time
(min)
In vivo
(ng per cm2)
In vitro SB-M
(ng per cm2)
In vitro FD-C
(ng per cm2)
(a) Stratum corneum (SC)
A 95 776.6 794.7±1049.7 607.3±698.9
185 664.3 1087.2±1400.7 977.6±1095.9
B 65 742.5 1259.1±1303.7 641.0±769.5
155 452.4 1121.8±1287.0 748.2±832.6
C (+ 75 min) 48
108
286.8
261.3
175.5±437.6
277.8±329.1
333.4±365.6
280.3±344.3
D 35 621.3 458.9±533.4 310.5±758.8
190 424.7 680.1±728.2 611.9±717.1
E (+ 60 min) 80
170
396.6
531.7
602.0±803.7
614.9±868.8
268.6±414.6
762.4±859.7
F 75 391.1 511.5±765.9 1088.0±1088.9
165 458.1 1024.9±1489.1 733.2±845.2
G (+ 40 min) 45
135
525.7
1406.0
686.3±818.7
511.6±735.3
393.5±432.2
570.5±661.1
H 100 496.2 488.9±494.5 433.2±479.2
190 200.8 574.4±911.6 424.8±442.9
(b) Deeper skin layers (DSL)
A 95 0 809.6±1270.1 0±0
185 626.4 1659.2±, 1920.9 610.6±777.8
B 65 427.6 660.9±983.3 117.7±135.1
155 1191.0 3028.4±4034.2 1580.9±2408.3
C (+ 75 min) 48
108
930.1
1156.0
1407.3±1548.5
2667.3±3266.5
625.4±634.5
1378.0±2033.6
D 35 276.4 1197.2±1287.8 0±0
190 1074.1 4394.6±5146.1 2470.8±2877.3
E (+ 60 min) 80
170
76.5
581.0
559.3±676.3
2976.5±3027.8
0±0
654.6±953.9
F 75 674.8 1274.2±2141.6 1110.9±1655.9
165 2015.0 5652.5±7001.9 3175.7±3287.4
G (+ 40 min) 45
135
435.3
1054.5
727.0±740.9
3779.8±4401.5
39.5±57.7
1242.2±2048.6
H 100 1080.9 2689.2±3676.5 1153.2±1339.4
190 1860.7 5985.3±8623.8 2664.1±3225.8
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No ¯ufenamic acid was found in either the ®lter paper beneath
the skin incubated in the SB-M nor in the Sùrensen phosphate
buffer pH 7.4 used as an additional acceptor medium in the FD-C.
DISCUSSION
The main difference between the in vivo and in vitro experiments is
the absence of perfusion within the DSL in the in vitro test series.
The blood circulation still present under in vivo conditions causes a
high tissue clearance by the blood stream and prevents the increase
of higher ¯ufenamic acid amounts not only in the SC, but also in
the DSL.
Using the FD-C, the tissue clearance may be simulated by the
buffer system beneath the skin in the acceptor compartment. But
the experimental conditions are nevertheless different from in vivo
ones, because the drug has to permeate through the whole skin
before an effect comparable with the transport with the blood
stream takes place. Therefore, the diffusion distance is much longer.
Besides, the diffusion of the drug may be affected by the diffusion
of the water from the aqueous part of the buffer solution in the
acceptor compartment. Both processes run in opposite directions
and possibly hinder each other. In addition, the buffer substances
change the pH within the DSL to a more neutral one (formerly
frozen skin and skin incubated in the SB-M: pH » 8.1; skin
incubated in the FD-C using the Sùrensen phosphate buffer pH 7.4
as the acceptor medium: pH » 7.4) and, therefore, lead to a
decreased solubility of the penetrating drug (unpublished data).
These events can be the reason why the drug amounts in the FD-C
are always lower than the ones in the SB-M, although a higher
water content in the tissue and especially in the SC leads to reduced
barrier functions of the SC and, therefore, higher drug amounts
within the skin should be obtained (Wiedmann, 1988; Alonso et al,
1996).
In the SB-M, unphysiologic hydration of the tissue is avoided;
however, the experimental design of this model leads to restricted
incubation times, because only the tissue itself acts as an acceptor
for the penetrating drug. In this case, no further clearance arises.
Concerning the absence of drug in the ®lter paper beneath the
skin in the SB-M as well as in the buffer solution in the FD-C,
these data indicate that sink conditions were maintained for all time
intervals investigated.
Apart from the mentioned reasons for the different results it has
to be kept in mind that some problems concerning the course of
the in vivo experiments had to be overcome, which also in¯uenced
the drug amount present in the skin and had to be simulated in an
appropriate way under in vitro conditions. In two cases due to high
traf®c volume or a late noti®cation from the hospital the arrival at
the hospital was delayed. The freezing of the skin biopsies was not
punctual after the excision and led to delays of 40±75 min
(Table I). Therefore, diffusion processes could not be stopped
immediately. Subsequently, there was a lower drug amount in the
SC. An additional problem was the single omission of the operating
team to remove the subcutaneous fatty tissue of the incubated skin
biopsies. The freezing of these biopsies was slower and penetration
of the drug within the skin specimens could not be completely
avoided. As mentioned in the Results concerning the in vitro
experiments, the differences between the drug amounts detected in
the SC after two different incubation times for one skin ¯ap were
sometimes low, or the longer incubation times led to less drug
amount than the shorter incubation time. The hypothesis was put
forward that quasi steady-state conditions in the SC might be
reached. Investigations concerning the calculation of quasi steady-
state conditions within the SC had been carried out previously
(Wagner et al, 2000) leading to time intervals from 6.6 6 3.0 up to
27.0 6 14.4 min, after which half of the quasi steady-state drug
amount in the SC was reached. These time intervals were relatively
short and might explain this phenomenon.
Concerning the SC an in vivo/in vitro correlation failed using the
represented methodology, although previous studies demonstrated
that a correlation could be achieved (Wagner et al, 2000). The main
difference of both studies is the application of disinfectant after the
removal of the incubated drug preparation. As illustrated in Fig 3
the disinfectant has a severe effect on the drug amount present in
the SC and the drug concentration±SC depth pro®le. Within the
®rst two-thirds of the SC the drug amount was reduced by 80%.
For the DSL, the described in¯uence of the disinfectant was
considered negligible as it was within the variation of the data
(detailed data not shown). Therefore, an in vivo/in vitro correlation
can be demonstrated for the DSL shown in Fig 4. A direct linear
correlation between in vivo and in vitro data was found for both
in vitro test systems leading to correlation coef®cients of r = 0.910
(SB-M vs in vivo; slope = 3.2272 6 0.3935) and r = 0.927 (FD-C
vs in vivo; slope = 1.7776 6 0.1926) in which both slopes are
statistically signi®cantly different from each other (Student's t test;
p < 0.01). This difference illustrates on the one hand the varying
in¯uence of the in vitro test systems on the drug penetration within
the skin. On the other hand, the calculated slopes represent a factor
about which in vivo and in vitro data are shifted against each other.
CONCLUSIONS
The described experimental design succeeded in establishing an
in vivo/in vitro correlation in the dermal ®eld of research using
human skin from the same subject for in vivo as well as in vitro
experiments. This correlation was convincing for the DSL, whereas
earlier data for the SC could not be con®rmed. Reasons for the
failure of the correlation within the SC could be attributed to the
in¯uence of the disinfectant. The results obtained with both in vitro
Figure 4. In vivo/in vitro correlation for deeper skin layers. Mean
of the data (ng per cm2) [n = 2 (in vitro) and n = 1 (in vivo); eight
subjects; two incubation times each].
Figure 3. In¯uence of the disinfectant on the drug amount in the
SC shown with an example of a 35 min application in the SB-M.
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test systems correlate in a satisfactory way with the in vivo data, but
the in vitro measurements overpredict the drug amounts in the DSL
(SB-M > FD-C). Nevertheless, this methodology could permit the
prediction of drug amounts penetrating into the DSL under in vivo
conditions after different incubation times as far as the lipophilic
model drug ¯ufenamic acid is concerned. Besides, it should have
the potential to decrease the number of in vivo experiments
followed by a reduction of the risks for volunteers and costs for the
development of new drug preparations.
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